The short answer: it depends on which GLP-1 you take — and it only matters if your contraception is a pill you swallow. Tirzepatide (Mounjaro and Zepbound) carries an FDA label warning that it can lower the effectiveness of oral hormonal contraceptives, so its label advises pill users to either switch to a non-oral method or add a barrier method such as condoms for 4 weeks after starting and for 4 weeks after every dose increase.[1] Semaglutide (Ozempic, Wegovy and Rybelsus) does not carry that warning — its label found no clinically relevant effect on the pill.[3] Non-oral methods — the IUD, implant, birth-control shot, patch and ring — are not affected by either drug. This is reference, not a prescription: which contraceptive you use is a decision for you and your clinician.
Which GLP-1s affect the pill — and what the label says to do
These are all in the same broad family (they are covered in our plain-language guide to how GLP-1 medicines work), but their labels are not identical. The contraception language differs by molecule, so the brand you are on matters.
| Medicine (active ingredient) | Does the label warn it can lower the pill's effectiveness? | What the label advises for people using an oral contraceptive |
|---|---|---|
| Mounjaro, Zepbound (tirzepatide) | Yes | Switch to a non-oral method, or add a barrier method (such as condoms) for 4 weeks after starting and for 4 weeks after each dose increase |
| Ozempic, Wegovy (semaglutide, injection) | No | No contraceptive-specific warning; no dose adjustment |
| Rybelsus (oral semaglutide) | No | No contraceptive-specific warning |
Notice what the tirzepatide warning does not cover: it applies only to contraception you swallow. Methods that bypass the stomach are not affected by either drug — more on those below.
Why would a weight-loss shot touch a birth control pill at all?
The link is mechanical, not hormonal. GLP-1 medicines slow how quickly the stomach empties into the intestine — that delayed emptying is part of why they curb appetite. But a swallowed birth control pill has to dissolve and be absorbed in the gut to reach your bloodstream. When the stomach empties more slowly, less of the pill's hormone can get absorbed on schedule, and its blood levels can dip.
Crucially, this is not the classic drug interaction you may have heard about with antibiotics or seizure medicines, where one drug revs up the liver enzymes that break hormones down. GLP-1s do not do that. The effect is purely about absorption — how much hormone makes it in, and when.[7] That single fact explains almost everything else on this page, including why non-oral methods are in the clear.
How big is the dip with tirzepatide? In the drug-interaction study behind the warning, a single 5 mg dose of tirzepatide was given alongside a standard combined pill. Peak blood levels of the estrogen component (ethinyl estradiol) fell by 59%, and the progestin components fell by 55% to 66%. Total exposure over the day dropped by roughly 20% to 23%, and absorption was delayed by about 3 to 4 hours.[2] The effect was largest after that first dose and diminished with later doses — which is exactly why the label ties its extra-protection advice to starting the drug and to each dose increase.[1]
Why tirzepatide but not semaglutide?
Both drugs slow gastric emptying, so it is fair to ask why only one gets a contraceptive warning. The answer is that the effect is bigger and more sustained with tirzepatide, and the makers of each drug tested the pill directly and got different results.
Novo Nordisk ran a dedicated study of semaglutide taken with a combined pill (ethinyl estradiol plus levonorgestrel). It did not find a clinically meaningful change in either hormone's exposure, and the FDA label reflects that: no contraceptive warning, and no dose adjustment needed.[3] Eli Lilly's tirzepatide study found the sizeable drops described above, and its label carries the switch-or-add-a-barrier advice.[5] This is one of the cleaner examples in this drug class of an evidence-graded difference: it is not a rumour or an "all GLP-1s probably do this" guess — it is two different labels reaching two different conclusions from their own trials.
A useful nuance: Rybelsus is itself an oral form of semaglutide, yet it still carries no contraceptive-switch warning. And these details are unrelated to what a drug is approved for — tirzepatide is FDA-approved for type 2 diabetes (Mounjaro) and for weight management and obstructive sleep apnoea in obesity (Zepbound), while semaglutide is approved for diabetes, cardiovascular risk reduction and weight management. The contraception difference tracks the molecule, not the brand's indication. If you take other daily medicines too, our interaction checker is a sensible place to start a conversation with your prescriber.
What about IUDs, implants, the patch and the ring?
Here is the reassuring part, and it follows directly from the mechanism. Because the problem is stomach absorption, any method that does not rely on swallowing is untouched by either drug. Neither tirzepatide nor semaglutide is expected to reduce the effectiveness of:
- A hormonal IUD (such as Mirena or Kyleena) or a copper IUD
- The contraceptive implant (such as Nexplanon)
- The birth-control injection (such as Depo-Provera)
- The contraceptive patch or the vaginal ring
That is why the tirzepatide label offers switching to a non-oral method as a full alternative to using condoms as backup — a non-oral method sidesteps the interaction entirely.[1] Whether a switch makes sense for you depends on your health history and preferences, so it is a conversation to have with your clinician rather than something to change on your own. If you also live with PCOS, our overview of choosing birth control with PCOS and the wider PCOS hub cover the trade-offs that are specific to that picture.
The "Ozempic baby" effect: two things happening at once
You may have seen headlines about "Ozempic babies" — unexpected pregnancies in women on GLP-1 medicines, sometimes after years of struggling to conceive. It is not one phenomenon but two effects stacking up, which is exactly why it catches people off guard.
First, with tirzepatide, the pill can simply become less reliable through the absorption effect described above. Second — and this applies to any GLP-1 — losing weight and improving insulin sensitivity can restart ovulation, particularly in people with PCOS, whose cycles may have been irregular or absent for years.[7] Restored fertility is often a welcome sign of better metabolic health, but if pregnancy is not the plan right now, it means contraception matters more on a GLP-1, not less.
This is where the stakes rise, because GLP-1 medicines are not considered safe in pregnancy. Animal studies have shown potential harm to the developing fetus, and human data are still limited and emerging.[6] For that reason the labels advise stopping the medicine before a planned pregnancy — Wegovy's label, for example, says to discontinue at least 2 months ahead because semaglutide clears from the body slowly.[4] We are quoting the label here, not setting your timing — the safe washout window and how to stop are decisions your prescriber will individualise for you.
Perimenopause is not birth control
One group this catches by surprise is women in their 40s and 50s. It is easy to assume that irregular perimenopausal cycles mean pregnancy is off the table — but ovulation can still happen until you are fully through menopause, and a GLP-1 that restores more regular cycles can quietly raise the odds. Pregnancy after 40 remains possible; we cover the specifics in can you get pregnant after menopause? If you are perimenopausal, on a GLP-1, and not planning a pregnancy, this is worth a direct question at your next appointment rather than an assumption.
When to see a doctor
Contraception and GLP-1 decisions belong with a prescriber, so most of this section is about when to make that call promptly:
- You think you might be pregnant while taking a GLP-1. Contact your clinician without delay — do not wait for a scheduled visit. Because these drugs are not considered safe in pregnancy, this is time-sensitive.
- You are on tirzepatide and take an oral contraceptive. Ask what backup or alternative your prescriber recommends around starting and around each dose increase, so you are covered during the windows the label flags.
- You are planning to conceive. Raise it early. The labels advise stopping the medicine ahead of a planned pregnancy, and your clinician will set the timing for you.[6]
- Severe, persistent abdominal pain — especially pain that bores through to your back, with or without vomiting — needs urgent medical attention, as it can signal pancreatitis, a recognised GLP-1 risk.
- You are considering compounded or online-sourced GLP-1s. Products from grey-market sellers may not match the tested labels this article relies on, and dosing can be inconsistent. Read how to get a GLP-1 online safely first, and keep a licensed prescriber in the loop.
What this actually means for you
Strip away the noise and it is a short, honest list. If you take tirzepatide (Mounjaro or Zepbound) and use the pill, the label wants you protected by a non-oral method or a barrier method during two specific windows. If you take semaglutide (Ozempic, Wegovy or Rybelsus), the pill is not flagged. If you use an IUD, implant, shot, patch or ring, neither drug changes the maths. And on any GLP-1, contraception matters more than usual, because fertility can return before you expect it and pregnancy is not the time to be on these medicines. None of that is a do-it-yourself instruction — it is what to bring to the person who prescribes for you, so the decision is made with your full picture in view.
